Biotechnology company SCG Cell Therapy has officially opened its new manufacturing facility and research and development centre at its headquarters in Singapore.
The company’s cGMP [current good manufacturing practice] facility leverages and expands the company’s expertise in advanced manufacturing and off-the-shelf human-induced pluripotent stem cell technology, with the support of the Singapore Economic Development Board.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
SCG’s partner hospitals in the Asia Pacific region, North America and Europe will receive cell therapy products from the new facility.
In 2021, SCG joined forces with the Cell Therapy Facility of the Singapore Health Sciences Authority (HSA-CTF) to undergo the validation process for its closed and automated cell therapy manufacturing system.
The system obtained accreditation from the US Food and Drug Administration and the HSA for clinical trials.
SCG Cell Therapy CEO Frank Wang stated: “In line with Singapore’s advanced manufacturing initiatives, the opening of this facility set an important milestone of cell therapy manufacturing advancement in the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“As our broad pipeline of cell therapy products progresses to the market, we look forward to further expanding our commercial-scale manufacturing capabilities in Singapore to deliver high-quality and affordable treatment to meet patients’ needs across Singapore, Asia-Pacific and the world.”
SCG is involved in the development of T-cell therapies, antibodies and therapeutic vaccines aimed at combating infections and preventing associated cancers.
